Abstract
The aim of this study was to investigate the impact of different antiretroviral therapy on the lipid status of HIV patients with emphasis on modern-generation drugs. A cross-sectional study was conducted at Clinic for Infectious Diseases at the University Clinical Center Kragujevac and included forty-six patients with HIV infection on antiretroviral therapy for a minimum of twelve months. Lipid status parameters were analyzed in relation to the length of administration and the type of antiretroviral therapy used (integrase inhibitors or other antiretroviral therapy groups). The average duration of antiretroviral therapy intake ± standard deviation was 5.59 ± 3.649. Statistically significant higher values of low-density lipoprotein cholesterol were recorded after six years of antiretroviral therapy that does not belong to the group of integrase inhibitors compared to a period of less than three years (p<0.05). After six years of the administration of all groups of antiretroviral therapy, low-density lipoprotein cholesterol and total cholesterol values increase significantly compared to all other groups (p<0,01 and p<0,05, respectively). Patients on integrase inhibitors therapy compared to other antiretroviral therapy groups, show statistically significant higher total cholesterol values (p<0,05). Although low-density lipoprotein cholesterol values show a tendency to increase over time in both (integrase inhibitors and other antiretroviral therapy) groups, they do not differ, which means that integrase inhibitors do not have a greater impact on low-density lipoprotein cholesterol growth. Despite the use of modern-generation antiretroviral therapy, dyslipidemia is present in a significant percentage of HIV patients.